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Abstract
Among end-stage  renal  disease  (ESRD)  patients  receiving  hemodialysis,  increased
arterial stiffness is an independent cardiovascular risk predictor. Over the past few
years,  arterial  stiffness  attenuation  has  been  increasingly  recognized  as  a  novel
therapeutic  target  toward cardiovascular  risk reduction in the dialysis  population.
Structural alterations related to the long-term arteriosclerotic process are difficult to
modify;  with  the  exception  of  blood  pressure  (BP)-lowering,  there  are  no  other
therapeutic interventions with well-documented benefits in delaying the progression
of  arteriosclerosis  among  dialysis  patients.  Enhanced  clearance  of  middle-to-high
molecular weight solutes by combining convective and diffusive transport through
hemodiafiltration and the associated benefits on microvascular endothelial function
have generated the hypothesis that convective dialytic modalities may be advanta‐
geous in improving large-artery stiffness. This notion is supported by some clinical
studies showing that switching ESRD patients from low-flux hemodialysis to high-
efficiency on-line hemodiafiltration was associated with significant reduction in arterial
stiffness. These beneficial effects, however, were not confirmed in a recent subanaly‐
sis  of  the  CONvective  TRAnsport  STudy  (CONTRAST)  trial.  In  this  chapter,  we
summarize the currently available evidence on the effect of hemodiafiltration versus
hemodialysis on arterial stiffness, discussing also the potential clinical implications of
this effect.
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1. Introduction
Patients with end-stage-renal-disease (ESRD) receiving maintenance hemodialysis have one
of  the  highest  rates  of  cardiovascular  morbidity  and mortality  [1,  2].  Although classical
atheromatosis of middle-sized arteries is an important contributor to this elevated cardio‐
vascular risk, atherosclerotic cardiovascular events (i.e., myocardial infarction and stroke)
can only partially explain the huge burden of cardiovascular mortality in ESRD. Among
these patients, serious arrhythmias and sudden cardiac deaths related to the high preva‐
lence of  left  ventricular  (LV) hypertrophy and disturbances in electrolyte  balance repre‐
sent another major cause of cardiovascular death [3]. This phenomenon is explained by the
fact that the spectrum of arterial remodeling in ESRD is much broader, including also long-
term structural alterations in the visco-elastic properties of the biomaterial constituting the
wall of the aorta and large conduit arteries [4, 5]. The so-called “arteriosclerotic process” is
accompanied by substantial  hemodynamic alterations and is considered one of the most
important pathogenic mechanisms of isolated systolic hypertension, LV hypertrophy, and
subendocardial  hypoperfusion  [4,  5].  It  is  therefore  unsurprising  that  among  ESRD pa‐
tients,  increased  arterial  stiffness  is  a  strong  and  powerful  predictor  of  cardiovascular
morbidity and mortality [6, 7].
Given the strong prognostic association of arterial stiffness with cardiovascular outcomes,
regression of the arteriosclerotic process is increasingly recognized as a novel therapeutic
target toward cardiovascular risk reduction in dialysis patients. However, whether arterial
stiffness in this particular population is modifiable and if so, which therapeutic interven‐
tions are effective in delaying the progression of arteriosclerosis are aspects that remain
unclear [5, 8]. Observational evidence and a few randomized studies suggested that blood
pressure (BP)-lowering and use of agents blocking the renin-angiotensin-aldosterone-
system (RAAS) may be of some benefit [5, 8, 9]. The modality of renal replacement therapy is
suggested to be another factor possibly determining the progression of arteriosclerosis in
dialysis patients. In this regard, higher clearance of middle-to-large molecular weight solutes
by combining diffusive and convective transport and the associated improvement in phos‐
phate control, endothelial dysfunction, and circulating inflammatory biomarkers [10–14] is
proposed to be translated into a beneficial impact of hemodiafiltration on large-artery
structure and function in dialysis patients.
The aim of this chapter was to review the currently available evidence on the effect of hemo‐
diafiltration versus hemodialysis on the long-term progression of the arteriosclerotic process
and discuss the potential implications that this effect may have in the choice of the most
appropriate dialytic modality for ESRD patients.
2. Arterial stiffness in dialysis patients
Acceleration of the arteriosclerotic process is the typical feature of arterial remodeling in
ESRD. Aortic and carotid-artery stiffness is significantly higher in ESRD patients than in
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age-, sex-, and BP-matched controls with normal renal function [15]. Among dialysis pa‐
tients, arteriosclerotic process is a pathophysiological continuum of structural alterations
that begin from the early stages of renal impairment, with several studies showing a step‐
wise increase in arterial stiffness with advancing stage of chronic kidney disease (CKD)
[16, 17]. Structural alterations related to arterial stiffening in ESRD include fibro-elastic
intimal thickening, calcification of elastic lamellae, increased extracellular matrix deposi‐
tion, elastynolysis and inflammation, increased collagen, and decreased elastic fiber con‐
tent [4, 18, 19]. The mechanistic background of these arterial wall alterations is complex
and not yet fully elucidated. Apart from the contribution of accumulated traditional cardi‐
ovascular risk factors, it is suggested that specific mechanistic pathways related to the
ESRD status and renal replacement therapy may play a particular role in the progression
of arteriosclerosis in this population. Some of the most important ESRD-specific mecha‐
nisms involved in the pathogenesis of arteriosclerosis include impaired mineral metabo‐
lism and elevated calcium-phosphate product, vascular calcification, excessive activation
of the RAAS, endothelial dysfunction, inflammation, oxidative stress, and chronic volume
overload [4, 18, 19]. Compared with traditional cardiovascular risk factors, these ESRD-
specific pathways were shown to be stronger determinants of the progression of arterio‐
sclerosis over time [20].
The main physiological role of the aorta and large conduit arteries is (i) to dampen the
high-pressure oscillations generated from the intermittent LV ejection and (ii) to transform
the cyclic blood flow in the aorta into a continuous capillary flow pattern required for
perfusion of organs and tissues [4, 19, 21]. During systole, the stroke volume ejected by
the left ventricle interacts with the elastic properties of the aorta to generate a pulse wave
(incident or forward-traveling) that is propagated at a pulse wave velocity (PWV) that
progressively increases across the arterial tree. Structure of the arterial system is normally
characterized by progressive increase in arterial wall stiffness from the ascending aorta to
the peripheral muscular-type arteries (so-called stiffness gradient) [4, 19, 21]. Impendence
mismatches at the transition between these segments generate pulse wave reflections.
These reflected waves travel from the periphery back to the ascending aorta (backward-
traveling reflected wave), opposing pulsatile energy transmission downstream to microcir‐
culation. In young subjects with elastic central arteries, this process is coupled with
slower pulse wave propagation and the overlap of the incident and reflected waves in the
ascending aorta occurs in late systole or early diastole. This phenomenon results in rise of
diastolic aortic pressure, favoring coronary perfusion during diastole. Arteriosclerotic
process, however, affects preferentially the wall of the aorta and large central arteries, re‐
versing the normal stiffness gradient between central and peripheral arterial segments
[22]. In conditions of accelerated arterial stiffness, such as ESRD, there is premature arriv‐
al of reflected waves back to the ascending aorta, during systole rather than diastole [4,
19, 21]. This results in augmentation of central aortic systolic pressure, thereby increasing
cardiac after load and promoting adverse myocardial remodeling toward fibrosis and hy‐
pertrophy. In addition, greater pulsatile energy transmission from macro- to microcircula‐
tion promotes microvascular damage in peripheral organs and tissues (Figure 1) [4, 19,
21].
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Figure 1. Pathophysiological role of increased arterial stiffness in ESRD.
The close pathophysiological association of arterial stiffness with promotion of end-organ
damage is in line with a strong epidemiological association of increased arterial stiffness with
worse cardiovascular outcomes. Among dialysis patients, prospective observational studies
have for long-connected higher aortic PWV with increased risk of all-cause and cardiovascular
mortality independently from other cardiovascular risk factors [7]. In the first study conducted
in the late 1990s in a cohort of 241 hemodialysis patients prospectively followed for a mean
period of 6 years, Blacher et al. [6] showed that the fully adjusted odds ratio (OR) for aortic
PWV > 12.0 versus PWV < 9.4 m/s was 5.4 [95% confidence intervals (CIs): 2.4–11.9] for all-
cause mortality and 5.9 (95% CI: 2.3–15.5) for cardiovascular mortality [6]. The strong prog‐
nostic association between aortic PWV and cardiovascular outcomes was confirmed in several
subsequent cohorts of hemodialysis patients [15, 23]. Similarly to patients receiving hemo‐
dialysis, more recent observational studies have demonstrated the strong and independent
prognostic significance of arterial stiffness in the whole spectrum of CKD, showing that aortic
PWV is an independent predictor of mortality in patients receiving peritoneal dialysis [24] in
renal transplant recipients [25] and in patients with CKD not yet on dialysis [26]. Most
importantly, regression of arterial stiffness in response to BP-lowering was shown to be
associated with improvement in survival [9], providing evidence that arterial stiffness is not
simply a risk predictor, but a true cardiovascular risk factor in the dialysis population.
3. Studies comparing the effect of hemodiafiltration versus hemodialysis
on arterial stiffness
Uremic toxin accumulation, particularly retention of protein-bound solutes and middle-
weight molecules as a result of their inadequate clearance through conservative dialytic
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modalities, is proposed to play a prominent role in promoting vascular atherosclerosis and
pathogenesis of cardiovascular disease among dialysis patients. In support of this notion,
background and clinical studies have shown that accumulation of p-cresol and indoxyl sulfate,
two protein-bound uremic toxins, acts as a triggering factor for the expression of pro-inflam‐
matory cytokines and adhesion molecules, induces shedding of endothelial microparticles,
and disrupts the nitric oxide signaling pathway [27–29]. Importantly, in recent prospective
observational studies, high concentrations of both p-cresol and indoxyl sulfate in hemodialysis
patients have been associated with increased risk of cardiovascular morbidity and mortality
independently from other traditional cardiovascular risk factors [30–32].
Hemodiafiltration is a dialytic modality that uses a combination of convective transport and
diffusion to enhance the removal of middle-to-high molecular weight solutes in comparison
with standard hemodialysis [33, 34]. In some clinical studies, enhanced middle-molecule
clearance achieved through convective dialytic modalities was shown to be associated with
improvement in phosphate control, better preservation of intradialytic hemodynamic stability,
as well as, with a number of beneficial actions on vasculature, such as reduction in circulating
markers of vascular inflammation and oxidative stress and improvement in flow-mediated
endothelium-dependent vasodilatation [11–14, 35]. These beneficial effects of hemodiafiltra‐
tion on the vasculature have generated the hypothesis that switching ESRD patients from
conventional hemodialysis to high-efficiency hemodiafiltration may be a therapeutic
maneuver with potential advantages in causing regression of arterial stiffness. This hypothesis
was tested in a number of clinical studies summarized in Table 1 and discussed in detail below.
Author Year n  Patient
characteristics
Design Intervention  Follow-up
(months) 
Change in arterial
stiffness over time
Overall
effect
Beerenhout
et al. [35]
2005 40 ESRD patients
treated with
thrice-weekly
low-flux HD
RCT Pre-dilution on-
line HDF versus
low-flux HD
12 Aortic PWV increased
similarly over time in
both dialytic
modalities (HDF: 12 ±
5 versus 13 ± 5 m/s;
HD: 12 ± 3 versus 13 ±
5 m/s)
Neutral
Bellien et al.
[37]
2014 42 ESRD patients
treated with
thrice-weekly
high-flux HD
RCT Post-dilution on-
line HDF versus
high-flux HD
4 Carotid artery
distensibility was
increased in the on-line
HDF group, but not in
the HD group
(between group
difference: −6.7 kPa−1 ×
10−3, 95% CI: −9.9 to
−3.5 kPa−1 × 10−3, P =
0.048)
Better
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Author Year n  Patient
characteristics
Design Intervention  Follow-up
(months) 
Change in arterial
stiffness over time
Overall
effect
Mostovaya
et al. [39]
2014 189 ESRD patients
participating in
the CONTRAST
trial
RCT Post-dilution on-
line HDF versus
low-flux HD
36 Aortic PWV remained
unchanged over time
with both dialytic
modalities (annual rate
of PWV change: HDF
group: −0.01, 95% CI:
−0.41 to 0.40 m/s/year;
HD group: −0.04, 95%
CI: −0.31 to 0.23 m/s/
year; p value HDF
versus HD: 0.89)
Neutral
Charitaki et
al. [38]
2014 289 ESRD patients
on maintenance
HD
Observational 69 patients on
low-flux HD
versus 78
patients switched
from low-flux
HD to HDF
versus 142
patients on HDF
6 Aortic PWV increased
over time in the low-
flux HD group (9.5 ±
1.9 versus 10.2 ± 2.2
m/s, p < 0.01) as well as
in the HD to HDF
group (9.4 ± 1.9 versus
10.1 ± 2.2 m/s, p < 0.01),
but remained constant
in the HDF group (9.9
± 2.1 versus 10.1 ± 2.2
m/s)
Better
Georgianos
et al. [36]
2014 48 ESRD patients
on maintenance
HD
Observational HDF versus low-
flux HD
Single
dialysis
session
Aortic PWV remained
unchanged from pre-
to postdialysis either
with HDF or with low-
flux HD (HDF: 9.3 ± 0.5
versus 9.4 ± 0.5 m/s, p
= 0.686 low-flux HD:
9.1 ± 0.4 versus 8.9 ±
0.4 m/s, p = 0.396)
Neutral
HD, hemodialysis; RCT, randomized controlled trial.
Table 1. Prospective studies comparing the effect of hemodiafiltration versus standard hemodialysis on arterial
stiffness.
3.1. Acute effects of hemodiafiltration on arterial stiffness
In a nested case-control design, Georgianos et al. [36] compared the acute changes in aortic
PWV from pre- to postdialysis in 24 ESRD patients receiving hemodiafiltration and in 24 age-
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and sex-matched controls receiving low-flux hemodialysis. Aortic PWV was not significantly
changed from pre- to postdialysis during both the first and second weekly dialysis sessions.
These modest acute changes in aortic PWV from pre- to postdialysis were no different between
the hemodiafiltration and low-flux hemodialysis groups in both dialysis sessions studied [36].
With regards to wave reflections, augmentation index and related parameters were signifi‐
cantly reduced from pre-to postdialysis in both dialysis sessions and patient groups. Similarly
to aortic PWV, intradialytic reduction in wave reflection indices was no different between
patients treated with hemodiafiltration and standard low-flux hemodialysis [36]. These
findings suggest an acute intradialytic improvement in wave reflections from the periphery
but not in aortic stiffness, an effect that was independent of the mode of dialysis. However,
these comparable acute alterations in large-artery cushioning function do not necessarily
prespecify the pattern of long-term progression of the arterial stiffness in patients treated with
different dialytic modalities.
3.2. Long-term effects of hemodiafiltration on arterial stiffness
Studies evaluating the long-term effects of hemodiafiltration relative to hemodialysis on
arterial structure and function provided contradictory results. Beerenhout et al. [35] random‐
ized 40 ESRD patients treated with conventional low-flux hemodialysis to switch to high-
efficiency pre-dilution on-line hemodiafiltration or to continue on the same dialytic modality.
After 12 months of follow-up, aortic PWV increased similarly in both low-flux hemodialysis
(12 ± 3 versus 13 ± 5 m/s) and on-line hemodiafiltration groups (12 ± 3 versus 13 ± 5 m/s).
Notably, change in 48-h ambulatory systolic and diastolic BP and in LV mass index over time
were also no difference between the two dialytic modalities [35]. Furthermore, on-line
hemodiafiltration was not superior to low-flux hemodialysis in inhibiting the formation of
advanced glycation end-products and reducing the circulating levels of asymmetric dimethy‐
larginine (ADMA) and markers of oxidative stress or total anti-oxidant capacity. In a subse‐
quent study, 42 ESRD patients were randomly assigned to switch from high-flux conventional
hemodialysis to high-efficiency post-dilution on-line hemodiafiltration or to remain on high-
flux hemodialysis for a mean follow-up period of 4 months [37]. Arterial stiffness assessed
with the use of the distensibility co-efficient of the common carotid artery was improved in
the on-line hemodiafiltration group, but not in the high-flux conventional hemodialysis group
(between-group difference: −6.7 kPa−1 × 10−3, 95% CI: −9.9 to −3.5 kPa−1 × 10−3, p = 0.048) [37].
Improvement in carotid artery distensibility was accompanied by a significant improvement
in Kt/V urea, predialysis levels of β2-microglobulin, circulating levels of ADMA and tumor
necrosis factor (TNF)-a, and brachial artery flow-mediated endothelium-dependent vasodila‐
tation. In a multiple regression analysis model, hemodiafiltration-induced improvement in
conduit artery endothelial dysfunction and stiffness was associated with the changes in Kt/V
urea and predialysis levels of β2-microglobulin, suggesting that enhanced clearance of middle-
to-high molecular weight solutes is one factor potentially contributing to the beneficial effect
of hemodiafiltration on large-artery stiffness.
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A beneficial effect of hemodiafiltration on arterial stiffness is supported by another observa‐
tional study, in which aortic PWV measurements were performed 6 months apart in three
different groups of ESRD patients [38]. The first group consisted of 69 ESRD patients receiving
conventional low-flux hemodialysis, the second group consisted of 78 ESRD patients who were
switched from low-flux hemodialysis to on-line hemodiafiltration, and the third group
included 142 ESRD patients receiving long-term renal replacement therapy with on-line
hemodiafiltration. Over the 6-month observational period, a significant increase in aortic PWV
was noted in those patients treated with hemodialysis (9.5 ± 1.9 versus 10.2 ± 2.2 m/s, p < 0.01)
as well as in those switched from hemodialysis to hemodiafiltration (9.4 ± 1.9 versus 10.1 ± 2.2
m/s, p < 0.01); in contrast, aortic PWV remained unchanged in the group of hemodiafiltration
(9.9 ± 2.1 versus 10.1 ± 2.2 m/s) [38]. The most important finding of this study was that aortic
PWV remained constant during follow-up only in those patients receiving long-term treatment
with hemodiafiltration, whereas aortic PWV increased in patients who were switched from
hemodialysis to hemodiafiltration. This observation could be interpreted in two different
ways: either the 6-month-long therapy with hemodiafiltration might be inadequate in order
to modify the arterial wall structure and stiffness, or aortic PWV increased in those patients
switched to hemodiafiltration due to a carry-on effect of previous long-term therapy with
conventional hemodialysis.
The above beneficial impact of hemodiafiltration in causing regression of arterial stiffness was
not confirmed in a recent subanalysis of 189 prevalent dialysis patients participating in the
CONvective TRAnsport STudy (CONTRAST) trial [39]. In this study, ESRD patients receiving
conventional low-flux hemodialysis were randomly assigned in a 1:1 ratio for treatment with
on-line hemodiafiltration or continuation of low-flux hemodialysis for a mean follow-up
period of 36 months. Median aortic PWV at baseline was 9.8 m/s (interquartile range: 7.5–12.0
m/s). Aortic PWV was not significantly changed over time, and the annual rate of PWV change
had no difference between the on-line hemodiafiltration and hemodialysis groups (hemodia‐
filtration group: −0.01 m/s/year, 95% CIs: −0.41 to 0.40 m/s/year; hemodialysis group: −0.04 m/
s/year, 95% CI: −0.31 to 0.23 m/s/year; p value for the between-group comparison: 0.89) [39].
The absence of difference between the two dialytic modalities in the rate of PWV change was
consistent across subgroups of age, sex, residual renal function, dialysis vintage, diabetes, and
history of pre-existing cardiovascular disease. Of note, the annual rate of PWV change had
once again no difference between the two dialytic modalities regardless of the convection
volume used for on-line hemodiafiltration (convection volume <18.9 L/session: 0.37 m/s/year;
95% CIs: −0.25 to 0.98 m/s/year, p = 0.23; convection volume >18.9 L/session: −0.01 m/s/year;
95% CIs: −0.59 to 0.57, p = 0.99) [39].
4. Studies comparing the effect of hemodiafiltration versus hemodialysis
on mortality
The above contradictory results of clinical studies that evaluated the comparative effectiveness
of hemodialfiltration versus standard hemodialysis in causing regression of arterial stiffness
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are in line with the uncertain superiority of hemodiafiltration on mortality across large-scaled
randomized controlled trials that included “hard” cardiovascular outcomes as primary
endpoints. For example, in the primary analysis of the aforementioned CONTRAST study [40],
714 ESRD patients were randomly assigned to switch from low-flux hemodialysis to on-line
hemodiafiltration or continue renal replacement therapy with low-flux hemodialysis. After a
mean follow-up period of 3 years, incidence of all-cause mortality [Hazard Ratio (HR): 0.95;
95% CIs: 0.75–1.20] and occurrence of fatal and non-fatal cardiovascular events (HR: 1.07; 95%
CIs: 0.83–1.39) were not different between the two dialytic modalities [40]. The subsequent
Turkish on-line hemodiafiltration (OL-HDF) study enrolled 782 ESRD patients receiving
standard thrice-weekly hemodialysis who were randomly assigned in a 1:1 ratio to post-
dilution on-line hemodiafiltration or high-flux conventional hemodialysis [41]. Over a mean
follow-up period of 22.7 ± 10.9 months, the occurrence of the composite primary outcome of
all-cause mortality and non-fatal cardiovascular event was identical in both study arms (event-
free survival of 77.6% in hemodiafiltration versus 74.8% in the high-flux group, P = 0.28) [41].
Contrary to the above results, the Estudio de Supervivencia de Hemodiafiltración On-Line
(ESHOL) study supports the notion that on-line hemodiafiltration is superior over hemodial‐
ysis in reducing all-cause and cardiovascular mortality [42]. In this open-label, randomized
controlled trial, 906 prevalent hemodialysis patients were randomly assigned either to switch
to high-efficiency post-dilution on-line hemodiafiltration or to remain on standard low-flux
hemodialysis. Switching from low-flux hemodialysis to on-line hemodiafiltration was
associated with a 30% risk reduction for all-cause mortality (HR: 0.70; 95% CI: 0.53–0.92), 33%
risk reduction for cardiovascular mortality (HR: 0.67; 95% CIs: 0.44–1.02) and 55% risk
reduction for infection-related mortality (HR: 0.45; 95% CIs: 0.21–0.96) [42].
5. Conclusion
In summary, the currently available evidence from observational and randomized clinical
studies does not conclusively support a clear superiority of hemodiafiltration versus standard
hemodialysis in improving arterial compliance. The contradictory results of clinical studies
with respect to PWV, a surrogate cardiovascular risk factor, are in line with the uncertain
survival benefit of convective dialytic modalities in large-scaled clinical trials evaluating
“hard” cardiovascular outcomes. Additional research efforts are urgently warranted to fully
elucidate the comparative effectiveness of hemodiafiltration versus conventional hemodialysis
on arterial stiffness attenuation. In the meantime, we believe that dialysis treatment optimi‐
zation is undoubtedly one useful tool toward cardiovascular risk reduction for patients
receiving maintenance hemodialysis.
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